Oncolytics Biotech Inc. provided an updated safety analysis for pelareorep, its intravenously delivered immunotherapeutic agent, which has been administered to over 1,200 patients. This extensive dataset includes more than 300 patients with various gastrointestinal tumors, demonstrating a consistent and favorable safety profile across multiple indications and in combination with numerous treatments.
The updated analysis confirms that the most common treatment-related adverse events (TRAEs) associated with pelareorep are Grade 1 and 2 flu-like symptoms, such as fever, chills, fatigue, nausea, vomiting, and diarrhea. Importantly, Grade 3 or 4 adverse events typically associated with chemotherapy do not appear to be modified by the addition of pelareorep to the treatment regimen.
Jared Kelly, CEO of Oncolytics, stated that with over 1,200 patients dosed and a consistent safety profile, pelareorep represents one of the most de-risked immunotherapies not yet approved as a treatment option in gastrointestinal tumors. This robust safety data is expected to be a positive characteristic for regulators and potential partners as the company advances towards registration-enabled studies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.